3823 related articles for article (PubMed ID: 12969539)
1. [Melanoma antigen genes(MAGE) and malignant tumors].
Xu JZ; Lin S
Ai Zheng; 2003 Sep; 22(9):1001-4. PubMed ID: 12969539
[TBL] [Abstract][Full Text] [Related]
2. The potential of melanoma antigen expression in cancer therapy.
Gillespie AM; Coleman RE
Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
[TBL] [Abstract][Full Text] [Related]
3. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
5. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
6. [Rejection antigens of tumors and specific immunotherapy of cancer].
Boon T; Lucas S
Bull Mem Acad R Med Belg; 1996; 151(12):469-79. PubMed ID: 9491625
[TBL] [Abstract][Full Text] [Related]
7. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
[TBL] [Abstract][Full Text] [Related]
8. The melanoma antigen genes--any clues to their functions in normal tissues?
Ohman Forslund K; Nordqvist K
Exp Cell Res; 2001 May; 265(2):185-94. PubMed ID: 11302683
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-associated antigen genes - an update.
Sang M; Wang L; Ding C; Zhou X; Wang B; Wang L; Lian Y; Shan B
Cancer Lett; 2011 Mar; 302(2):85-90. PubMed ID: 21093980
[TBL] [Abstract][Full Text] [Related]
11. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.
Tanzarella S; Lionello I; Valentinis B; Russo V; Lollini PL; Traversari C
Cancer Immunol Immunother; 2004 Jun; 53(6):519-24. PubMed ID: 14727086
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy.
Ries J; Schultze-Mosgau S; Neukam F; Diebel E; Wiltfang J
Int J Oncol; 2005 Mar; 26(3):817-24. PubMed ID: 15703841
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of tumor rejection antigen peptides recognized by specific CTL].
Uenaka A; Nakayama E
Nihon Rinsho; 1996 Jan; 54(1):242-9. PubMed ID: 8587197
[TBL] [Abstract][Full Text] [Related]
14. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
[TBL] [Abstract][Full Text] [Related]
15. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
17. [Tumor rejection antigen and cancer immunotherapy].
Matsutake T; Nakayama E
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115
[TBL] [Abstract][Full Text] [Related]
18. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
Trakatelli M; Toungouz M; Lambermont M; Heenen M; Velu T; Bruyns C
Cancer Gene Ther; 2005 Jun; 12(6):552-9. PubMed ID: 15665821
[TBL] [Abstract][Full Text] [Related]
19. Tumor antigen expression in melanoma varies according to antigen and stage.
Barrow C; Browning J; MacGregor D; Davis ID; Sturrock S; Jungbluth AA; Cebon J
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):764-71. PubMed ID: 16467087
[TBL] [Abstract][Full Text] [Related]
20. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
van den Eynde B
Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]